290 related articles for article (PubMed ID: 30468097)
1. Review of studies reporting actual prices for medicines.
Mardetko N; Kos M; Vogler S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
[TBL] [Abstract][Full Text] [Related]
2. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
3. Enhancing medicine price transparency through price information mechanisms.
Hinsch M; Kaddar M; Schmitt S
Global Health; 2014 May; 10():34. PubMed ID: 24885767
[TBL] [Abstract][Full Text] [Related]
4. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
5. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
6. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
[TBL] [Abstract][Full Text] [Related]
7. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
Morgan SG; Vogler S; Wagner AK
Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
[TBL] [Abstract][Full Text] [Related]
8. The economics of parallel trade.
Danzon PM
Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
[TBL] [Abstract][Full Text] [Related]
9. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
Carapinha JL
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
Moodley R; Suleman F
BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
[TBL] [Abstract][Full Text] [Related]
11. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
Russo G; McPake B
Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
[TBL] [Abstract][Full Text] [Related]
12. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
13. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
14. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
15. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
Russo P; Carletto A; Németh G; Habl C
Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
[TBL] [Abstract][Full Text] [Related]
16. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
17. Evidence on the effectiveness of policies promoting price transparency - A systematic review.
Joosse IR; Tordrup D; Glanville J; Kotas E; Mantel-Teeuwisse AK; van den Ham HA
Health Policy; 2023 Aug; 134():104681. PubMed ID: 36372608
[TBL] [Abstract][Full Text] [Related]
18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
19. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
20. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]